SLN
OTC MARKETS · Biotechnology
Silence Therapeutics PLC
$19.80
+0.03 (+0.15%)
Financial Highlights (FY 2026)
Revenue
14.75M
Net Income
-31,237,785
Gross Margin
37.8%
Profit Margin
-231.4%
Rev Growth
+315.5%
D/E Ratio
2.02
Income Statement
| FY 2026 | |
|---|---|
| Revenue | 14.75M |
| Gross Profit | 5.58M |
| Operating Income | -40,966,947 |
| Net Income | -31,237,785 |
| Gross Margin | 37.8% |
| Operating Margin | -277.7% |
| Profit Margin | -231.4% |
| Rev Growth | +315.5% |
Balance Sheet
| FY 2026 | |
|---|---|
| Total Debt | 428.08M |
| Total Equity | 211.85M |
| D/E Ratio | 2.02 |
Cash Flow
| FY 2026 | |
|---|---|
| EBITDA | -35,003,763 |
| Free Cash Flow | — |